Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064632 | 0.84 | MGLL (0.41) | P2RX7ADRB1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15873874 | 0.80 | P2RX7 (0.44) | P2RX7ADRB1JAK2BTK | |
| SCHEMBL7093301 | 0.79 | HTR2C (0.40) | ADRB1SOS1HTR2AHTR2CHTR2B | |
| SCHEMBL3653056 | 0.78 | ADRB1 (0.54) | P2RX7ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL31176347 | 0.78 | ADRB1 (0.54) | P2RX7ADRB1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5913602 | 0.77 | ADRB1 (0.53) | P2RX7ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL16197593 | 0.77 | HSD17B10 (0.50) | P2RX7 | |
| SCHEMBL123449 | 0.76 | HSD17B10 (0.45) | P2RX7JAK2BTK | |
| SCHEMBL13664823 | 0.74 | SLC6A2 (0.53) | P2RX7ADRB1HTR2AHTR2CHTR2B | |
| SCHEMBL3650828 | 0.74 | HTR6 (0.58) | P2RX7HTR2ACXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311749-A1 | 4-BENZOYL-1-SUBSTITUTED-PIPERAZIN-2-ONE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| EP-2212300-A1 | 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009053459-A1 | 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311749-A1 | 4-BENZOYL-1-SUBSTITUTED-PIPERAZIN-2-ONE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885ADRB1 629/4885JAK2 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.